Cytochrome P450 enzymes (CYPs) and flavin-containing monooxygenases (FMOs) likely have a role in the oxidation of intermediate metabolites of busulfan (Bu). In vitro studies to investigate the involvement of these enzymes are cumbersome because of the volatile nature of the intermediate metabolite tetrahydrothiophene (THT) and the lack of sensitive quantitation methods. This study explored the association between the CYP2C9, CYP2C19, CYP2B6 and FMO3 genotypes and sulfolane (Su, a water soluble metabolite of Bu) plasma levels in children undergoing hematopoietic stem cell transplantation (HSCT). The relationship between these genotypes and the effectiveness of myeloablative conditioning was also analyzed. Sixty-six children receiving an intr...
Hematologic malignancies are the most frequent cancers in the pediatric population. Despite the high...
Hepatic venoocclusive disease (HVOD) in bone marrow transplantation (BMT) is attributed to toxicity ...
This doctoral work has comprehensively evaluated the pharmacokinetics and pharmacogenetics of Busulf...
Allogenic hematopoietic stem cell transplantation (HSCT) is a well established but complex treatment...
Busulphan (Bu) is an alkylating agent used in the conditioning regimen prior to hematopoietic stem c...
<div><p>Busulphan (Bu) is an alkylating agent used in the conditioning regimen prior to hematopoieti...
Allogenic hematopoietic stem cell transplantation (HSCT) is a well-established but complex treatment...
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for several malignant and non...
Hemorrhagic cystitis (HC) is one of the complications of busulfan-cyclophosphamide (BU-CY) condition...
Busulfan (BU) is a key compound in conditioning myeloablative regimens for children undergoing hemat...
Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of...
Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of...
Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of...
For patients with myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) rema...
The role of busulfan (Bu) metabolites in the adverse events seen during hematopoietic stem cell tran...
Hematologic malignancies are the most frequent cancers in the pediatric population. Despite the high...
Hepatic venoocclusive disease (HVOD) in bone marrow transplantation (BMT) is attributed to toxicity ...
This doctoral work has comprehensively evaluated the pharmacokinetics and pharmacogenetics of Busulf...
Allogenic hematopoietic stem cell transplantation (HSCT) is a well established but complex treatment...
Busulphan (Bu) is an alkylating agent used in the conditioning regimen prior to hematopoietic stem c...
<div><p>Busulphan (Bu) is an alkylating agent used in the conditioning regimen prior to hematopoieti...
Allogenic hematopoietic stem cell transplantation (HSCT) is a well-established but complex treatment...
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for several malignant and non...
Hemorrhagic cystitis (HC) is one of the complications of busulfan-cyclophosphamide (BU-CY) condition...
Busulfan (BU) is a key compound in conditioning myeloablative regimens for children undergoing hemat...
Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of...
Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of...
Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of...
For patients with myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) rema...
The role of busulfan (Bu) metabolites in the adverse events seen during hematopoietic stem cell tran...
Hematologic malignancies are the most frequent cancers in the pediatric population. Despite the high...
Hepatic venoocclusive disease (HVOD) in bone marrow transplantation (BMT) is attributed to toxicity ...
This doctoral work has comprehensively evaluated the pharmacokinetics and pharmacogenetics of Busulf...